Filing Details
- Accession Number:
- 0000950170-24-026098
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-03-05 16:39:07
- Reporting Period:
- 2024-03-03
- Accepted Time:
- 2024-03-05 16:39:07
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 818686 | Teva Pharmaceutical Industries Ltd | TEVA | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1995297 | L Vikki Conway | C/O Teva Pharmaceutical Industries Ltd. 124 Dvora Hanevi'A St., Tel Aviv L3 6944020 | See "Remarks" | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Acquisiton | 2024-03-03 | 5,179 | $0.00 | 8,107 | No | 4 | M | Direct | |
| Ordinary Shares | Disposition | 2024-03-04 | 1,490 | $13.37 | 6,617 | No | 4 | S | Direct | |
| Ordinary Shares | Acquisiton | 2024-03-04 | 7,117 | $0.00 | 13,734 | No | 4 | M | Direct | |
| Ordinary Shares | Disposition | 2024-03-04 | 2,042 | $13.37 | 11,692 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Ordinary Shares | Restricted Share Units | Disposition | 2024-03-03 | 5,179 | $0.00 | 5,179 | $0.00 |
| Ordinary Shares | Restricted Share Units | Disposition | 2024-03-04 | 7,117 | $0.00 | 7,117 | $0.00 |
| Ordinary Shares | Restricted Share Units | Acquisiton | 2024-03-04 | 33,482 | $0.00 | 33,482 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 15,538 | No | 4 | M | Direct | ||
| 14,237 | No | 4 | M | Direct | ||
| 33,482 | No | 4 | A | Direct |
Footnotes
- The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
- The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 21, 2023.
- Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.25 to $13.445, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
- Restricted share units were granted on March 3, 2023, with 5,179 vesting on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 5,180 vesting on March 3, 2027.
- Restricted share units were granted on March 4, 2022, with 7,117 vesting on each of March 4, 2024 and March 4, 2025, and 7,120 vesting on March 4, 2026.
- Restricted share units were granted on March 4, 2024, with 8,370 vesting on each of March 4, 2025, March 4, 2026 and March 4, 2027, and 8,372 vesting on March 4, 2028.
Billionaire Hedge Funds
